From making condoms to steering clear of costly formulations, the drugmaker’s strategy of taking the road less travelled could now give it a seat at the high table.
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
$99 for one year
A couple of antibiotics that have the potential to change the beleaguered company’s fortunes need a quick infusion of funds to get across the finish line. Can Khorakiwala, the 82-year-old chairman, pull it off?
With a promoter who is unafraid to make bold bets and pivot to businesses holding more promise, investors can only look forward to better times.
The Hyderabad-based generics maker has seen its stock scale all-time highs and lows in quick succession. With big plans in place and regulatory heat easing, its roller-coaster days may be over.